Severe infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria
Conditions
Interventions
Vancomycin Anti-Infective Treatment Observation Group:The dosing regimen in accordance with the Chinese Expert Consensus on Vancomycin Application Dosage or their own clinical experience.
Vancomycin Anti-Infection Treatment Intervention Group:Patient-specific parameters are input into the established PBPK model to conduct virtual simulations, predicting steady-state exposure levels (in
Sponsors
The First Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult inpatients (>=18 years, regardless of sex) who receive intravenous vancomycin therapy between July 2026 and February 2027 for severe infections diagnosed as methicillin-resistant Staphylococcus aureus (MRSA). 2. Patients with complete clinical data, including age, sex, height, body weight, steady-state trough concentration of vancomycin, clinical diagnosis, concomitant medications administered for more than 2 days (e.g., digoxin, diuretics, antimicrobial agents, etc.), as well as liver function parameters (ALT, AST) and renal function parameter (Cr) measured on the day before or within several days prior to medication administration; 3. Patients with serum creatinine levels within the normal range (53–106 µmol/L for adult males, 44–97 µmol/L for adult females); 4. Patients who voluntarily sign the informed consent form and are able to cooperate in completing the study.
Exclusion criteria
Exclusion criteria: 1. Patients aged 106 µmol/L for adult males; 97 µmol/L for adult females); 6. Patients who have participated in other interventional clinical trials within 30 days prior to enrollment; 7. Patients with other conditions deemed unsuitable for enrollment by the investigator (e.g., estimated life expectancy <72 hours, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vancomycin Trough Level ; | — |
Secondary
| Measure | Time frame |
|---|---|
| The rate of achieving target vancomycin steady-state trough concentrations among patients; | — |
Countries
China
Contacts
Public ContactWu Xinan
The First Hospital of Lanzhou University
Outcome results
None listed